Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab in Schnitzler syndrome
NL-OMON40255Phase 2Active, not recruiting
- Sponsor
- Servier
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gevokizumab in Schnitzler syndrome, sponsored by Servier. Primary endpoint: Exploratory descriptive endpoints on efficacy and safety. Started Dec 2013; status: active, not recruiting.
02
Drugs
gevokizumab
03
Conditions
Schnitzler syndrome
Beyond the preview
Go deeper on NL-OMON40255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40255.